|
adult |
21 |
|
hepatocellular carcinoma |
21 |
|
cirrhosis |
19 |
|
entecavir |
17 |
|
chronic hepatitis b |
16 |
|
liver transplantation |
16 |
|
antiviral therapy |
14 |
|
female |
14 |
|
humans |
14 |
|
male |
14 |
|
middle aged |
14 |
|
nafld |
14 |
|
aged |
13 |
|
hepatitis b |
13 |
|
adolescent |
12 |
|
aged, 80 and over |
12 |
|
hbv |
12 |
|
medical sciences |
12 |
|
prediction |
12 |
|
risk factors |
12 |
|
dna, viral - blood |
11 |
|
hepatitis b virus |
11 |
|
longitudinal studies |
11 |
|
genotype |
10 |
|
hong kong - epidemiology |
10 |
|
liver stiffness |
10 |
|
age factors |
9 |
|
antiviral |
9 |
|
asian continental ancestry group - statistics & numerical data |
9 |
|
biomarker |
9 |
|
child |
9 |
|
child, preschool |
9 |
|
follow-up studies |
9 |
|
infant |
9 |
|
liver fibrosis |
9 |
|
nash |
9 |
|
non-viral liver disease |
9 |
|
pre-s deletions |
9 |
|
tumorigenesis |
9 |
|
antiviral agents - therapeutic use |
8 |
|
cardiac function |
8 |
|
hbsag |
8 |
|
hepatitis b virus - genetics |
8 |
|
high-intensity focused ultrasound |
8 |
|
hla‐dp |
8 |
|
ifn‐γ pathway |
8 |
|
liver transplant |
8 |
|
nephrotoxicity |
8 |
|
nucleoside analogues |
8 |
|
tenofovir |
8 |
|
transarterial chemoembolization |
8 |
|
waiting list |
8 |
|
abdominal abscess |
7 |
|
abdominal bleeding |
7 |
|
cancer staging |
7 |
|
cancer survival |
7 |
|
cap |
7 |
|
carcinoma, hepatocellular - etiology |
7 |
|
carcinoma, hepatocellular - virology |
7 |
|
controlled attenuation parameter |
7 |
|
de novo hbv |
7 |
|
de novo hepatocellular carcinoma |
7 |
|
disease progression |
7 |
|
etv |
7 |
|
extended criteria organ |
7 |
|
gastroenterology medical sciences |
7 |
|
hepatitis b virus - physiology |
7 |
|
hepatitis b, chronic - complications |
7 |
|
kidney transplantation |
7 |
|
lamivudine |
7 |
|
liver cirrhosis - etiology |
7 |
|
liver neoplasms - virology |
7 |
|
long-term survival |
7 |
|
natural history |
7 |
|
nucleos(t)ide analogue |
7 |
|
nucleoside analogue |
7 |
|
primary biliary cirrhosis |
7 |
|
surface antigen |
7 |
|
surgery |
7 |
|
treatment outcome |
7 |
|
virus replication |
7 |
|
adefovir |
6 |
|
alanine aminotransferase |
6 |
|
alanine transaminase - blood |
6 |
|
aspartate aminotransferase |
6 |
|
biliary complications |
6 |
|
carcinoma, hepatocellular - diagnosis - epidemiology |
6 |
|
carcinoma, hepatocellular - ethnology - pathology - virology |
6 |
|
carcinoma, hepatocellular - etiology - pathology - surgery - virology |
6 |
|
cholangiograms |
6 |
|
drug resistance, viral |
6 |
|
drug therapy, combination |
6 |
|
ductal anomaly |
6 |
|
elasticity imaging techniques |
6 |
|
endocrinology |
6 |
|
fatty liver |
6 |
|
genotype 1 |
6 |
|
genotype 6 |
6 |
|
hbeag |
6 |
|
hbv dna |
6 |
|
hepacivirus - classification - genetics - pathogenicity |
6 |
|
hepaticolenticular degeneration |
6 |
|
hepatitis b - complications |
6 |
|
hepatitis b antibodies - blood |
6 |
|
hepatitis b surface antigen |
6 |
|
hepatitis b surface antigens - immunology |
6 |
|
hepatitis b virus - drug effects |
6 |
|
hepatitis b virus - genetics - immunology - isolation & purification |
6 |
|
hepatitis b virus - isolation and purification |
6 |
|
hepatitis b(e) antigen |
6 |
|
hepatitis b, chronic - blood - complications - genetics |
6 |
|
hepatitis b, chronic - complications - drug therapy |
6 |
|
hepatitis b, chronic - ethnology - immunology - pathology |
6 |
|
hepatitis c |
6 |
|
hepatitis c, chronic - complications - metabolism - virology |
6 |
|
hepatocellullar carconoma |
6 |
|
hepatocholangiocarcinoma |
6 |
|
host-pathogen interactions |
6 |
|
intrahepatic cholangiocarcinoma |
6 |
|
kinetics |
6 |
|
lamivudine - pharmacology - therapeutic use |
6 |
|
liver - pathology - virology |
6 |
|
liver cirrhosis - complications - diagnosis |
6 |
|
liver cirrhosis - ethnology - pathology - virology |
6 |
|
liver neoplasms - diagnosis - epidemiology |
6 |
|
liver neoplasms - ethnology - pathology - virology |
6 |
|
liver neoplasms - etiology |
6 |
|
liver neoplasms - etiology - pathology - surgery - virology |
6 |
|
living donor liver transplantation |
6 |
|
m2bpgi |
6 |
|
mac-2 binding protein glycosylation isomer |
6 |
|
mass screening - methods |
6 |
|
metabolic syndrome |
6 |
|
mortality |
6 |
|
mutation - genetics |
6 |
|
nomogram |
6 |
|
platelet ratio index |
6 |
|
predictive value of tests |
6 |
|
primary biliary cholangitis |
6 |
|
proportional hazards models |
6 |
|
prospective studies |
6 |
|
recurrence |
6 |
|
resection |
6 |
|
reverse transcriptase inhibitors - therapeutic use |
6 |
|
right liver donation |
6 |
|
risk factor |
6 |
|
seroepidemiologic studies |
6 |
|
sex factors |
6 |
|
time factors |
6 |
|
transplantation |
6 |
|
ursodeoxycholic acid |
6 |
|
viral core proteins - genetics |
6 |
|
viral load |
6 |
|
virus dna |
6 |
|
young adult |
6 |
|
alkaline phosphatase - blood |
5 |
|
alpha-fetoproteins - analysis |
5 |
|
antiviral agents - administration and dosage - therapeutic use |
5 |
|
aspartate aminotransferases - blood |
5 |
|
bilirubin - blood |
5 |
|
china |
5 |
|
deceased-donor liver re-transplantation |
5 |
|
deep sequencing |
5 |
|
dna, circular - analysis - isolation & purification |
5 |
|
dna, viral - analysis |
5 |
|
dna, viral - analysis - isolation & purification |
5 |
|
drugs, chinese herbal - adverse effects |
5 |
|
epidemiology |
5 |
|
fibrosis |
5 |
|
freezing |
5 |
|
gamma-glutamyltransferase - blood |
5 |
|
gene expression regulation, viral |
5 |
|
globulins - analysis |
5 |
|
graft failure |
5 |
|
guanine - administration and dosage - analogs and derivatives - therapeutic use |
5 |
|
hbeag seroconversion |
5 |
|
hepacivirus - genetics |
5 |
|
hepatic artery thrombosis |
5 |
|
hepatitis b surface antigens - blood |
5 |
|
hepatitis b surface antigens - blood - chemistry |
5 |
|
hepatitis b surface antigens - genetics |
5 |
|
hepatitis b surface antigens - metabolism |
5 |
|
hepatitis b virus - classification - genetics |
5 |
|
hepatitis b virus - genetics - immunology - isolation and purification |
5 |
|
hepatitis b virus - genetics - isolation and purification |
5 |
|
hepatitis b virus dna rebound |
5 |
|
hepatitis b, chronic - blood - drug therapy |
5 |
|
hepatitis b, chronic - blood - drug therapy - virology |
5 |
|
hepatitis b, chronic - complications - virology |
5 |
|
hepatitis b, chronic - drug therapy |
5 |
|
hepatitis b, chronic - drug therapy - enzymology - immunology |
5 |
|
hepatitis b, chronic - drug therapy - virology |
5 |
|
hepatitis b, chronic - epidemiology - physiopathology - virology |
5 |
|
hepatitis b, chronic - pathology |
5 |
|
hepatitis c, chronic - drug therapy - virology |
5 |
|
interferon-alpha - therapeutic use |
5 |
|
lamivudine - therapeutic use |
5 |
|
liver |
5 |
|
liver - metabolism |
5 |
|
liver - virology |
5 |
|
liver biochemistry |
5 |
|
liver cirrhosis - diagnosis |
5 |
|
liver diseases - etiology |
5 |
|
living-donor liver re-transplantation |
5 |
|
medicine, chinese traditional - adverse effects |
5 |
|
models, biological |
5 |
|
nucleosides - pharmacology - therapeutic use |
5 |
|
polyethylene glycols - therapeutic use |
5 |
|
protein precursors - genetics |
5 |
|
protein stability |
5 |
|
pyrimidinones - pharmacology - therapeutic use |
5 |
|
quantitative |
5 |
|
quasispecies |
5 |
|
recombinant proteins |
5 |
|
resistance |
5 |
|
reverse transcriptase polymerase chain reaction |
5 |
|
ribavirin - therapeutic use |
5 |
|
rna, messenger - analysis - isolation & purification |
5 |
|
rna, viral - analysis - isolation & purification |
5 |
|
roc curve |
5 |
|
specimen handling - methods |
5 |
|
statistics, nonparametric |
5 |
|
stopping |
5 |
|
transient elastography |
5 |
|
treatment guidelines |
5 |
|
tumor |
5 |
|
viral suppression |
5 |
|
week 12 |
5 |
|
week 24 |
5 |
|
adenine - analogs & derivatives - therapeutic use |
4 |
|
age distribution |
4 |
|
antibody-mediated rejection |
4 |
|
antiviral agents - pharmacology - therapeutic use |
4 |
|
asian continental ancestry group |
4 |
|
asian continental ancestry group - ethnology |
4 |
|
biomarkers |
4 |
|
carcinoma, hepatocellular - diagnosis - virology |
4 |
|
case-control studies |
4 |
|
cohort studies |
4 |
|
dna, circular - analysis |
4 |
|
dose-response relationship, immunologic |
4 |
|
drug resistance, multiple, viral - genetics |
4 |
|
drug resistance, viral - genetics |
4 |
|
elasticity |
4 |
|
elasticity imaging techniques - methods |
4 |
|
guanine - analogs & derivatives - therapeutic use |
4 |
|
hbv infection |
4 |
|
hepatitis b - immunology - prevention & control |
4 |
|
hepatitis b antibodies - blood - immunology |
4 |
|
hepatitis b core-related antigen |
4 |
|
hepatitis b e antigen (hbeag) |
4 |
|
hepatitis b e antigens - blood |
4 |
|
hepatitis b vaccines - administration & dosage - immunology |
4 |
|
hepatitis b virus (hbv) dna |
4 |
|
hepatitis b virus - drug effects - genetics |
4 |
|
hepatitis b virus rna |
4 |
|
hepatitis b, chronic - blood - drug therapy - genetics |
4 |
|
hepatitis b, chronic - blood - drug therapy - immunology |
4 |
|
hepatitis b, chronic - complications - drug therapy - ethnology |
4 |
|
hepatitis b, chronic - diagnosis |
4 |
|
hepatitis b, chronic - enzymology - pathology |
4 |
|
hong kong |
4 |
|
immunization schedule |
4 |
|
immunization, secondary |
4 |
|
immunogenicity |
4 |
|
immunologic memory |
4 |
|
lamivudine - administration & dosage |
4 |
|
liver - pathology |
4 |
|
liver cirrhosis - diagnosis - epidemiology - virology |
4 |
|
liver neoplasms - diagnosis - virology |
4 |
|
long-term |
4 |
|
mutation |
4 |
|
phosphonic acids - therapeutic use |
4 |
|
pneumocystis jirovecii |
4 |
|
pneumocystis pneumonia |
4 |
|
post-liver transplant |
4 |
|
prevalence |
4 |
|
retrospective studies |
4 |
|
reverse transcriptase inhibitors - administration & dosage |
4 |
|
sex distribution |
4 |
|
transplants |
4 |
|
vaccination |
4 |
|
vaccines, dna - administration & dosage - immunology |
4 |
|
adoptive immunity transfer |
3 |
|
age of onset |
3 |
|
alcoholic liver disease |
3 |
|
anti-ulcer agents - therapeutic use |
3 |
|
chi-square distribution |
3 |
|
chronic disease |
3 |
|
chronic hepatitis b therapy |
3 |
|
chronic viral infection |
3 |
|
drug resistance |
3 |
|
end-stage liver disease |
3 |
|
erectile dysfunction |
3 |
|
esophagitis - drug therapy - ethnology |
3 |
|
esophagoscopy |
3 |
|
etiology |
3 |
|
gastric acidity determination |
3 |
|
gastro-oesophageal reflux disease |
3 |
|
guanine - adverse effects - analogs & derivatives - pharmacology - therapeutic use |
3 |
|
hbv vaccination |
3 |
|
hepatitis b immune globulin |
3 |
|
hepatitis b surface antigens - blood - immunology |
3 |
|
hepatitis b treatment |
3 |
|
hepatitis b virus - drug effects - genetics - isolation & purification |
3 |
|
hepatitis b, chronic - diagnosis - drug therapy - immunology - virology |
3 |
|
hepatitis b, chronic - epidemiology |
3 |
|
hepatitis c, chronic - epidemiology |
3 |
|
hydrogen-ion concentration |
3 |
|
hypogonadism |
3 |
|
immunologic factors - therapeutic use |
3 |
|
interferons |
3 |
|
lb80380 |
3 |
|
liver cirrhosis, biliary - epidemiology |
3 |
|
liver diseases - epidemiology - etiology |
3 |
|
liver diseases, alcoholic - epidemiology |
3 |
|
logistic models |
3 |
|
manometry |
3 |
|
nucleotide analogue |
3 |
|
oesophagitis |
3 |
|
omeprazole - therapeutic use |
3 |
|
ph monitoring |
3 |
|
phosphonic acids - adverse effects - pharmacology - therapeutic use |
3 |
|
practice guidelines as topic |
3 |
|
proton pump inhibitors |
3 |
|
questionnaires |
3 |
|
severity of illness index |
3 |
|
sexual dysfunction |
3 |
